HighGravityDataCurrent guidance
5 items
DexCom
Guidance from DexCom’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 30, 2026
Data checked
Jul 30, 2026
What changed in the Jul 30, 2026 release
Each item compared with the same item in the previous release (Apr 30, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Narrowed | Revenue | for FY2026 | “$5.16 - $5.25 billion (approximately 11-13% growth)” | “$5.18 - $5.25 billion (approximately 11-13% growth)” | Filing ↗ |
| Raised | Adjusted EBITDA Margin | for FY2026 | “approximately 31-31.5%” | “approximately 31.5-32%” | Filing ↗ |
| Raised | Non-GAAP Operating Margin | for FY2026 | “approximately 23-23.5%” | “approximately 23.5-24%” | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Revenue | “$5.18 - $5.25 billion (approximately 11-13% growth)” | for FY2026 | GAAP-tied | Apr 30, 2026 | 2 | Filing ↗ |
| Total revenue | “$5.16 - $5.25 billion” | for FY2026 | GAAP-tied | Jan 7, 2026 | 1 | Filing ↗ |
| Adjusted EBITDA Margin | “approximately 31.5-32%” | for FY2026 | Company-defined | Apr 30, 2026 | 2 | Filing ↗ |
| Non-GAAP Gross Profit Margin | “approximately 63-64%” | for FY2026 | Company-defined | Jan 7, 2026 | 2 | Filing ↗ |
| Non-GAAP Operating Margin | “approximately 23.5-24%” | for FY2026 | Company-defined | Jan 7, 2026 | 3 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Share repurchase program | “$750 million” | — | Declared action | May 1, 2025 | 1 | Filing ↗ |
How one item moved
Non-GAAP Operating Margin, for FY2026 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2026 | FY2025 | FY2024 | No period |
|---|---|---|---|---|
| Revenue | 2 statements | 3 statements | 1 statement | — |
| Total revenue | 1 statement | 1 statement | — | — |
| Adjusted EBITDA Margin | 2 statements | 3 statements | 1 statement | — |
| Non-GAAP Gross Profit Margin | 2 statements | 5 statements | 2 statements | — |
| Non-GAAP Operating Margin | 3 statements | 5 statements | 2 statements | — |
The full record for DexCom and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 30, 2026 | FY2026 Q2 | 0001093557-26-000142 | 3 | Open filing ↗ |
| Apr 30, 2026 | FY2026 Q1 | 0001093557-26-000072 | 4 | Open filing ↗ |
| Jan 7, 2026 | FY2025 Q4 | 0001093557-26-000003 | 5 | Open filing ↗ |
| Oct 30, 2025 | FY2025 Q3 | 0001093557-25-000278 | 4 | Open filing ↗ |
| Jul 25, 2025 | FY2025 Q2 | 0001093557-25-000241 | 4 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0001093557-25-000111 | 5 | Open filing ↗ |
| Jan 13, 2025 | FY2024 Q4 | 0001093557-25-000004 | 5 | Open filing ↗ |
| Oct 24, 2024 | FY2024 Q3 | 0001093557-24-000179 | 5 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error